Rating Rationale
December 28, 2018 | Mumbai
Zydus Technologies Limited
Rating removed from 'Watch Developing'; Rating Reaffirmed
 
Rating Action
Total Bank Loan Facilities Rated Rs.227 Crore
Long Term Rating CRISIL AA+(SO)/Stable (Removed from 'Rating Watch with Developing Implications'; Rating reaffirmed)
1 crore = 10 million
Refer to annexure for Details of Instruments & Bank Facilities
Detailed Rationale

CRISIL has removed its rating on the bank facilities of Zydus Technologies Limited (ZTL) from   'Rating Watch with Developing Implications'. The rating has been reaffirmed at 'CRISIL AA+(SO)' and assigned a 'Stable' outlook.
 
The rating action is in line with a similar revision on the rating on ZTL's parent, Cadila Healthcare Ltd (Cadila Healthcare; 'CRISIL AA+/Stable/CRISIL A1+'). The rating has been removed from watch following clarifications regarding the funding of the Zydus Cadila group's acquisition of Heinz India Pvt Ltd (Heinz; subsidiary of The Kraft Heinz Company), and the synergies expected between the two entities.
 
ZTL's rating is based upon an unconditional, continuing and irrevocable guarantee from Cadila Healthcare, and an unconditional undertaking by the latter for securing principal and interest obligation on the company's entire debt. The payment structure is designed to ensure full and timely payment to the lender. The guarantor, Cadila Healthcare, will pay, not later than seven business days from the due date, any amount due and payable by ZTL, in relation to these instruments, in case of any default on, or shortfall in, payment. The guarantee and the undertaking together cover the principal, interest, and other monies payable under the loan.

Analytical Approach

CRISIL has applied its approach of rating instruments backed by guarantee. Also, unsecured loans have been treated as neither debt nor equity as they are from the parent and subordinated to bank loans.

Key Rating Drivers & Detailed Description
Strengths
* Creditworthiness of the guarantor
Cadila Healthcare is the flagship company of the Zydus Cadila group. The group is one of the top five players in India branded formulations market and amongst the top ten players in the US generics markets. It is the market leader in the high-growth lifestyle segments such as gastrointestinal, respiratory and gynaecology. The Zydus Cadila group's strong position in the domestic formulations market is supported by its established brands, a large and therapeutic-focussed field force, in-licensing agreements, and product launches. Business prospects are supported by a growing presence in the regulated generics markets such as the US, and the rest of the world markets such as Brazil and South Africa. 

* Strong support from the parent for project funding
Till September 30, 2018, Rs 880 crore has been spent on the ongoing project which is funded with external commercial borrowing of Rs 220 crore and rest from the parent through equity, preference share capital and unsecured loans. Financial support from Cadila Healthcare is likely to continue, given the strategic importance to, and strong business and financial linkages with, the parent.
 
Weakness
* Exposure to project-related technology and implementation risks
The company intends to develop, manufacture, and market a defined range of transdermal generic drugs using new drug delivery system technologies in several therapeutic areas in the US and other global markets, besides India. Transdermal formulations are niche and difficult to develop and manufacture. Because of the niche product segment and stringent regulatory requirements, there is exposure to technology and implementation risks associated with the project.
Outlook: Stable

The outlook is based on the 'Stable' outlook on the guarantor's debt instruments. The ratings will remain sensitive to any change in CRISIL's rating on Cadila Healthcare.
 
Liquidity
Liquidity is adequate marked by support from Cadila Healthcare. ZTL's commercial operations are yet to commence while repayment on the term loan started from May 2018. Timely infusion of funds by the parent for the ongoing project and term debt repayments supports ZTL's liquidity. Term debt repayment is about Rs 80 crore annually (USD 11.29 million) till fiscal 2021. Financial support from Cadila Healthcare is likely to continue, given the strategic importance to, and strong business and financial linkages with, the parent.

About the Company

ZTL was incorporated in 2009 as an 85:15 joint venture between Cadila Healthcare and Dr Sharad Govil, respectively. The company has been formed to develop, manufacture, and market a defined range of transdermal (non-oral) generic drugs, using new drug delivery system technologies, in several therapeutic areas in the US and other global markets, besides India. It has set up a unit in the special economic zone near Ahmedabad, Gujarat. The construction of the project was completed in fiscal 2014. Production is expected to commence in fiscal 2019, on commercial launch of the product in the US.
 
About Cadila Healthcare
Founded as Cadila Laboratories Ltd (Cadila Laboratories) by Mr Ramanbhai Patel in 1952, Cadila Healthcare was formed in 1995, following a split in Cadila Laboratories, with Mr Indravadan Modi and his family's share being moved to a company called Cadila Pharmaceuticals Ltd. The division that was managed by Mr Ramanbhai Patel's son, Mr Pankaj Patel, was renamed Cadila Healthcare. In 2000, it got listed on the Bombay Stock Exchange. As on September 30, 2018, the promoters held 74.79% stake in Cadila Healthcare, foreign portfolio investors held 8.70%, and the balance by the public and others.

Key Financial Indicators*
Particulars Unit 2018 2017
Revenue Rs crore NA NA
Adjusted Profit after tax (PAT) Rs crore NA NA
Adjusted PAT margin % NA NA
Adjusted debt/adjusted net worth Times NA NA
Interest coverage Times NA NA
*Project company

Any other information: Not applicable

Note on complexity levels of the rated instrument:
CRISIL complexity levels are assigned to various types of financial instruments. The CRISIL complexity levels are available on www.crisil.com/complexity-levels. Users are advised to refer to the CRISIL complexity levels for instruments that they consider for investment. Users may also call the Customer Service Helpdesk with queries on specific instruments.
Annexure - Details of Instrument(s)
ISIN Name of Instrument Date of Allotment Coupon Rate (%) Maturity Date Issue Size
(Rs. Cr)
Rating Assigned
with Outlook
NA Long Term Loan NA NA 15-May-20 164 CRISIL AA+(SO)/Stable
NA Proposed Long Term
Bank Loan Facility
NA NA NA 63 CRISIL AA+(SO)/Stable
Annexure - Rating History for last 3 Years
  Current 2018 (History) 2017  2016  2015  Start of 2015
Instrument Type Outstanding Amount Rating Date Rating Date Rating Date Rating Date Rating Rating
Fund-based Bank Facilities  LT/ST  227.00  CRISIL AA+(SO)/Stable  25-10-18  CRISIL AA+(SO)/Watch Developing  28-06-17  CRISIL AA+(SO)/Stable  27-12-16  CRISIL AA+(SO)/Stable  21-09-15  CRISIL AA+(SO)/Stable  CRISIL AA+(SO)/Stable 
        29-06-18  CRISIL AA+(SO)/Positive      19-12-16  Withdrawal       
All amounts are in Rs.Cr.
Annexure - Details of various bank facilities
Current facilities Previous facilities
Facility Amount (Rs.Crore) Rating Facility Amount (Rs.Crore) Rating
Long Term Loan 164 CRISIL AA+(SO)/Stable Long Term Loan 227 CRISIL AA+(SO)/Watch Developing
Proposed Long Term Bank Loan Facility 63 CRISIL AA+(SO)/Stable -- 0 --
Total 227 -- Total 227 --
Links to related criteria
CRISILs Approach to Financial Ratios
CRISILs Bank Loan Ratings - process, scale and default recognition
Criteria for rating instruments backed by guarantees
Rating criteria for manufaturing and service sector companies
Rating Criteria for the Pharmaceutical Industry
CRISILs Bank Loan Ratings

For further information contact:
Media Relations
Analytical Contacts
Customer Service Helpdesk
Saman Khan
Media Relations
CRISIL Limited
D: +91 22 3342 3895
B: +91 22 3342 3000
saman.khan@crisil.com

Naireen Ahmed
Media Relations
CRISIL Limited
D: +91 22 3342 1818
B: +91 22 3342 3000
naireen.ahmed@crisil.com

Vinay Rajani
Media Relations
CRISIL Limited
D: +91 22 3342 1835
M: +91 91 676 42913
B: +91 22 3342 3000
vinay.rajani@ext-crisil.com

Anuj Sethi
Senior Director - CRISIL Ratings
CRISIL Limited
D:+91 44 6656 3100
anuj.sethi@crisil.com


Sameer Charania
Director - CRISIL Ratings
CRISIL Limited
D:+91 22 4097 8025
sameer.charania@crisil.com


Varsha Chandwani
Rating Analyst - CRISIL Ratings
CRISIL Limited
D:+91 22 3342 3163
Varsha.Chandwani@crisil.com
Timings: 10.00 am to 7.00 pm
Toll free Number:1800 267 1301

For a copy of Rationales / Rating Reports:
CRISILratingdesk@crisil.com
 
For Analytical queries:
ratingsinvestordesk@crisil.com


 

Note for Media:
This rating rationale is transmitted to you for the sole purpose of dissemination through your newspaper / magazine / agency. The rating rationale may be used by you in full or in part without changing the meaning or context thereof but with due credit to CRISIL. However, CRISIL alone has the sole right of distribution (whether directly or indirectly) of its rationales for consideration or otherwise through any media including websites, portals etc.


About CRISIL Limited

CRISIL is a leading agile and innovative, global analytics company driven by its mission of making markets function better. We are India’s foremost provider of ratings, data, research, analytics and solutions. A strong track record of growth, culture of innovation and global footprint sets us apart. We have delivered independent opinions, actionable insights, and efficient solutions to over 1,00,000 customers.
 
We are majority owned by S&P Global Inc., a leading provider of transparent and independent ratings, benchmarks, analytics and data to the capital and commodity markets worldwide.
 
For more information, visit www.crisil.com 


Connect with us: TWITTER | LINKEDIN | YOUTUBE | FACEBOOK

About CRISIL Ratings
CRISIL Ratings is part of CRISIL Limited (“CRISIL”). We pioneered the concept of credit rating in India in 1987. CRISIL is registered in India as a credit rating agency with the Securities and Exchange Board of India (“SEBI”). With a tradition of independence, analytical rigour and innovation, CRISIL sets the standards in the credit rating business. We rate the entire range of debt instruments, such as, bank loans, certificates of deposit, commercial paper, non-convertible / convertible / partially convertible bonds and debentures, perpetual bonds, bank hybrid capital instruments, asset-backed and mortgage-backed securities, partial guarantees and other structured debt instruments. We have rated over 24,500 large and mid-scale corporates and financial institutions. CRISIL has also instituted several innovations in India in the rating business, including rating municipal bonds, partially guaranteed instruments and microfinance institutions. We also pioneered a globally unique rating service for Micro, Small and Medium Enterprises (MSMEs) and significantly extended the accessibility to rating services to a wider market. Over 1,10,000 MSMEs have been rated by us.


CRISIL PRIVACY
 
CRISIL respects your privacy. We may use your contact information, such as your name, address, and email id to fulfil your request and service your account and to provide you with additional information from CRISIL.For further information on CRISIL’s privacy policy please visit www.crisil.com.


DISCLAIMER

This disclaimer forms part of and applies to each credit rating report and/or credit rating rationale that we provide (each a “Report”). For the avoidance of doubt, the term “Report” includes the information, ratings and other content forming part of the Report. The Report is intended for the jurisdiction of India only. This Report does not constitute an offer of services. Without limiting the generality of the foregoing, nothing in the Report is to be construed as CRISIL providing or intending to provide any services in jurisdictions where CRISIL does not have the necessary licenses and/or registration to carry out its business activities referred to above. Access or use of this Report does not create a client relationship between CRISIL and the user.

We are not aware that any user intends to rely on the Report or of the manner in which a user intends to use the Report. In preparing our Report we have not taken into consideration the objectives or particular needs of any particular user. It is made abundantly clear that the Report is not intended to and does not constitute an investment advice. The Report is not an offer to sell or an offer to purchase or subscribe for any investment in any securities, instruments, facilities or solicitation of any kind or otherwise enter into any deal or transaction with the entity to which the Report pertains. The Report should not be the sole or primary basis for any investment decision within the meaning of any law or regulation (including the laws and regulations applicable in the US).

Ratings from CRISIL Rating are statements of opinion as of the date they are expressed and not statements of fact or recommendations to purchase, hold, or sell any securities / instruments or to make any investment decisions. Any opinions expressed here are in good faith, are subject to change without notice, and are only current as of the stated date of their issue. CRISIL assumes no obligation to update its opinions following publication in any form or format although CRISIL may disseminate its opinions and analysis. CRISIL rating contained in the Report is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment or other business decisions. The recipients of the Report should rely on their own judgment and take their own professional advice before acting on the Report in any way.CRISIL or its associates may have other commercial transactions with the company/entity.

Neither CRISIL nor its affiliates, third party providers, as well as their directors, officers, shareholders, employees or agents (collectively, “CRISIL Parties”) guarantee the accuracy, completeness or adequacy of the Report, and no CRISIL Party shall have any liability for any errors, omissions, or interruptions therein, regardless of the cause, or for the results obtained from the use of any part of the Report. EACH CRISIL PARTY DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY, SUITABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall any CRISIL Party be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs) in connection with any use of any part of the Report even if advised of the possibility of such damages.

CRISIL Ratings may receive compensation for its ratings and certain credit-related analyses, normally from issuers or underwriters of the instruments, facilities, securities or from obligors. CRISIL’s public ratings and analysis as are required to be disclosed under the regulations of the Securities and Exchange Board of India (and other applicable regulations, if any) are made available on its web sites, www.crisil.com (free of charge). Reports with more detail and additional information may be available for subscription at a fee – more details about CRISIL ratings are available here: www.crisilratings.com.

CRISIL and its affiliates do not act as a fiduciary. While CRISIL has obtained information from sources it believes to be reliable, CRISIL does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives and / or relies in its Reports. CRISIL keeps certain activities of its business units separate from each other in order to preserve the independence and objectivity of the respective activity. As a result, certain business units of CRISIL may have information that is not available to other CRISIL business units. CRISIL has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process. CRISIL has in place a ratings code of conduct and policies for analytical firewalls and for managing conflict of interest. For details please refer to: https://www.crisil.com/en/home/our-businesses/ratings/regulatory-disclosures/highlighted-policies.html

CRISIL’s rating criteria are generally available without charge to the public on the CRISIL public web site, www.crisil.com. For latest rating information on any instrument of any company rated by CRISIL you may contact CRISIL RATING DESK at CRISILratingdesk@crisil.com, or at (0091) 1800 267 1301.

This Report should not be reproduced or redistributed to any other person or in any form without a prior written consent of CRISIL.

All rights reserved @ CRISIL